Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Completed · Phase 2

Conditions studied: Kidney Neoplasms, Carcinoma, Renal Cell

In brief

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Key facts

Study ID

NCT00282048

Run by

Pfizer

People needed

62

Starts

2006-03-01

Expected to finish

2009-06-01

Last updated by the study team

2012-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• RCC with metastases and nephrectomy
• failure of prior sorafenib-based therapy
• at least 1 target lesion that has not been irradiated
• adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

You may not qualify if…

• Gastrointestinal abnormalities
• current use or inability to avoid chronic antacid therapy
• current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2 inducers
• active seizure disorder or evidence of brain metastases.

Where it is running

• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — The Bronx, New York, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.